Phase III ELEVATE TN Trial #ASH19 #ASH @TheUSONetwork
Jeff Sharman, MD of @TheUSONetwork discusses the phase III ELEVATE TN trial.
_______
Read here:
Related Articles
Hagop Kantarjian: Only 9 Free Seats | 33 Top Hem KOLs, La Jolla AML-ALL
We are excited to extend a special discounted invitation for the next 9 hematologists to register for the upcoming AML-ALL Meeting in La Jolla, CA…
ASCO 2024: Phase 3 IMROZ Study: Sarclisa (Isatuximab) + VRd in Transplant-Ineligible NDMM Patients
Explore the longer treatment duration and consistent benefits of Sarclisa in patients with multiple myeloma who are ineligible for transplant.
Promising Phase 2 Results for Zanidatamab in HER2+ Biliary Tract Cancer: ASCO 2024 Update
Exciting updates from ASCO 2024: Learn about the potential of zanidatamab, a bispecific HER2 antibody, in improving treatment outcomes for HER2-positive biliary tract cancer (BTC).
ASCO 2024: Phase 3 IMROZ Study: Sarclisa (Isatuximab) + VRd in Transplant-Ineligible NDMM Patients
Explore the longer treatment duration and consistent benefits of Sarclisa in patients with multiple myeloma who are ineligible for transplant.
ASCO 2024: Phase 3 IMROZ Study: Sarclisa (Isatuximab) + VRd in Transplant-Ineligible NDMM Patients
Explore the longer treatment duration and consistent benefits of Sarclisa in patients with multiple myeloma who are ineligible for transplant.
ASCO 2024: Palbociclib, Pembrolizumab, & Endocrine therapy in HR+/HER2- locally advanced or metastatic breast cancer (MBC) – Alexis LeVee, MD – City of Hope
Get insights into the pivotal clinical trial exploring the combination of palbociclib, pembrolizumab, and endocrine therapy in patients with HR+/HER2- metastatic breast cancer.
Impact of Latino Ethnicity on Gut Microbiome in mRCC: ASCO 2024 Study – Regina Barragan-Carillo, Phd – City of Hope
Find out how Latino ethnicity affects the gut microbiome and clinical outcomes in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
High-Dose Chemotherapy for Recurrent Germ Cell Tumors: ASCO 2024 Study Results – Hedyeh Ebrahimi, MD – City of Hope
Discover the latest study on the effectiveness of high-dose chemotherapy for recurrent germ cell tumors. Get insights from leading referral centers.
Program Guide – ASCO Meeting Program Guide
Abhay Singh Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Abhay Singh, Megan Herr, Rahul Mishra, Rusina Karia, Theresa Hahn,…
briansjourney | Twitter, Instagram, Facebook, TikTok | Linktree
Hey, it’s me Brian O. I’m just a blood cancer warrior. Grateful for another day